Aimmune™ Therapeutics – Allergy Immunology
Returning guest, Dr. Steve Tilles, Senior Director of Medical Affairs at Aimmune Therapeutics, the first company to gain FDA approval of a peanut allergy treatment, PALFORZIA™, discusses his experience as an allergist, where the allergy immunology market is headed over the next year and provides real-world insight into practices reopening in light of COVID-19.
Frequently Asked Questions
What is the main topic discussed in this episode of Health Professional Radio?
This episode covers important developments in healthcare, including updates on COVID. Health Professional Radio brings you expert insights and analysis on the latest medical news affecting healthcare professionals and patients alike.
How can healthcare professionals benefit from this information?
Healthcare professionals can stay informed about the latest developments in COVID and related fields, enabling them to provide better patient care. Staying current with medical news helps clinicians make evidence-based decisions in their practice.
Where can I find more information about COVID?
For more detailed information, listen to the full episode on Health Professional Radio and visit hpr.fm for additional resources. You can also subscribe to our podcast for regular updates on healthcare news and expert interviews.
Key Takeaways
- Key Point: Steve Tilles, Senior Director of Medical Affairs at Aimmune Therapeutics, the first company to gain FDA approval of a peanut allergy treatment, PALFORZIA™, discusses his exper…
- Key Point: Tilles, MD, is Senior Director of Medical Affairs at Aimmune Therapeutics.
- Key Point: In addition to this role, he is a Fellow of the American Academy of Allergy, Asthma & Immunology (AAAAI) and the American College of Allergy, Asthma, and Immunology (ACAAI).
- Key Point: Previously, he served as President of the ACAAI.
- Key Point: Tilles has been a principal investigator for more than 140 clinical trials involving treatments for asthma, allergic rhinitis, urticaria and atopic dermatitis, as well as 13 tri…
Stephen A. Tilles, MD, is Senior Director of Medical Affairs at Aimmune Therapeutics. In addition to this role, he is a Fellow of the American Academy of Allergy, Asthma & Immunology (AAAAI) and the American College of Allergy, Asthma, and Immunology (ACAAI). Previously, he served as President of the ACAAI. Dr. Tilles has been a principal investigator for more than 140 clinical trials involving treatments for asthma, allergic rhinitis, urticaria and atopic dermatitis, as well as 13 trials evaluating treatments for food allergy. He has authored more than 100 papers in peer-reviewed publications. He has appeared on various lists including “Seattle’s Best Doctors”, “Seattle Super Doctors”, “Washington’s Best Doctors”, and “America’s Best Doctors”.
Medical Disclaimer
The information provided on this website is for general informational purposes only and is not intended as medical advice. Always consult with a qualified healthcare professional for medical advice, diagnosis, or treatment. Never disregard professional medical advice or delay in seeking it because of something you have read on this website.


